Effects of Intravitreal Aflibercept on the Systemic Insulin-like Growth Factor-I and Vascular Endothelial Growth Factor-A in Patients with Diabetic Retinopathy and Age-Related Macular Degeneration.
Journal
Journal of ophthalmology
ISSN: 2090-004X
Titre abrégé: J Ophthalmol
Pays: United States
ID NLM: 101524199
Informations de publication
Date de publication:
2021
2021
Historique:
received:
31
08
2021
accepted:
18
11
2021
entrez:
27
12
2021
pubmed:
28
12
2021
medline:
28
12
2021
Statut:
epublish
Résumé
To analyze the effect of intravitreal aflibercept injections on systemic levels of insulin-like growth factor-1 and vascular endothelial growth factor-A in patients with diabetic retinopathy and age-related macular degeneration. Vascular endothelial growth factor-A and insulin-like growth factor-1 levels were determined before and one week and four weeks after intravitreal injection of aflibercept (2.0 mg/50 A significant decline in systemic vascular endothelial growth factor-A level, from 43 (30-57) pg/ml at baseline to 8 (8-8) pg/ml ( The difference between the baseline systemic insulin-like growth factor-1 levels of the age-related macular degeneration and diabetic retinopathy groups and the higher insulin-like growth factor-1 levels in the proliferative diabetic retinopathy subgroup one week after aflibercept therapy suggest that insulin-like growth factor-1 may play a role in the pathomechanism of diabetic retinopathy.
Identifiants
pubmed: 34956670
doi: 10.1155/2021/7058505
pmc: PMC8694974
doi:
Types de publication
Journal Article
Langues
eng
Pagination
7058505Informations de copyright
Copyright © 2021 Anna Lena Huber et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
BMJ Open Ophthalmol. 2019 Mar 20;4(1):e000185
pubmed: 30997397
Mol Vis. 2011;17:2318-24
pubmed: 21921983
Cells. 2019 Aug 14;8(8):
pubmed: 31416218
J Clin Invest. 2004 Apr;113(8):1149-57
pubmed: 15085194
Ophthalmology. 2000 Dec;107(12):2224-32
pubmed: 11097601
BMJ Open. 2017 Sep 1;7(9):e016280
pubmed: 28864696
Diabetol Int. 2018 Apr 26;10(1):3-11
pubmed: 30800559
Biol Rev Camb Philos Soc. 2017 Aug;92(3):1755-1768
pubmed: 27779364
Diabetes Metab. 2019 Dec;45(6):517-527
pubmed: 31005756
Lancet. 2010 Jul 10;376(9735):124-36
pubmed: 20580421
Mol Cancer Ther. 2012 Jul;11(7):1576-86
pubmed: 22700681
Diabetes. 1998 Jun;47(6):859-66
pubmed: 9604860
Curr Eye Res. 2018 Mar;43(3):368-375
pubmed: 29172741
J Diabetes Res. 2019 Mar 27;2019:6456032
pubmed: 31049357
Br J Ophthalmol. 2014 Dec;98(12):1636-41
pubmed: 25001321
Ophthalmology. 2003 Sep;110(9):1677-82
pubmed: 13129861
Aging (Albany NY). 2018 Dec 29;10(12):4241-4247
pubmed: 30594908
Am J Ophthalmol. 2004 Mar;137(3):486-95
pubmed: 15013873
Invest Ophthalmol Vis Sci. 2014 Mar 19;55(3):1607-15
pubmed: 24550358
Arch Ophthalmol. 2004 Apr;122(4):477-85
pubmed: 15078664
Am J Ophthalmol. 2007 Oct;144(4):627-37
pubmed: 17893015
J Clin Endocrinol Metab. 1997 Sep;82(9):2806-8
pubmed: 9284700
Invest Ophthalmol Vis Sci. 2011 Jan 05;52(1):93-100
pubmed: 20720219
Nat Med. 1999 Dec;5(12):1390-5
pubmed: 10581081
Acta Ophthalmol. 2015 Mar;93(2):e154-9
pubmed: 25488124
Ophthalmology. 2008 Jan;115(1):116-26
pubmed: 17675159
J Clin Invest. 1993 Dec;92(6):2620-5
pubmed: 7504689
Ophthalmology. 1997 Oct;104(10):1661-9
pubmed: 9331208